問卷

TPIDB > Principal Investigator

Principal Investigator



更新時間:2023-09-19

詹宜學
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

2Cases

2019-03-01 - 2024-12-26

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2019-03-01 - 2023-12-31

Phase III

A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy
  • Condition/Disease

    Advanced Hepatocellular Carcinoma

  • Test Drug

    Cabozantinib (XL184) 20mg and 60mg tablet; Atezolizumab 1200mg/ 20ml solution for IV infusion

Participate Sites
9Sites

Recruiting7Sites

Terminated2Sites